【摘要】 目的:探讨乳腺癌患者HER4与HER2、ER、PR之间的关系及其对乳腺癌预后的影响。方法:采用免疫组化SP法检测105例乳腺癌组织中HER4、HER2、ER、PR蛋白的表达。对患者随访,随访终点为无病生存时间(disease free survival,DFS)。结果:HER2、HER4、ER、PR在105例乳腺癌患者中的阳性表达率分别为:37.14%、20.00%、40.00%、28.27%;HER4与年龄、淋巴结转移、分期、肿瘤类型以及是否化疗的差异性均无统计学意义(P﹥0.05);HER4可刺激ER、PR产生(P=0.030,P=0.028);HER4阳性与阴性患者无病生存时间差异有统计学意义(P=0.039);HER4(+)HER2(-)组乳腺癌患者较其他组无病生存时间明显延长(P=0.000)。结论:HER4可作为独立的临床预后因子,HER4可延长乳腺癌患者无病生存时间并可刺激ER、PR的产生。更多还原

【Abstract】 Objective:To investigate the relationship between expression of HER4,HER2,ER and PR and evaluate them on the clinical prognosis of human breast carcinoma.Methods:The expressions of HER4,HER2,ER and PR were studied in 105 cases with breast carcinoma by using SP immunohistochemistry.The endpoint of follow-up was disease free survival(DFS).Results:HER2,HER4,ER and PR expression were detected in 105 cases with positive rates of 37.14%,20.00%,40.00%,28.27%,respectively.The expression intensity of HER2,HER4,ER and PR in breast carcinoma had no significant correlation with the age,lymph node metastasis,pathological types,TNM stage,chemotherapy of the patients(P > 0.05).HER4 can be a co-activator of ER and PR expression(P = 0.030,P = 0.028).Compared with those with HER4-positive profiles,patients with HER4-negative profiles had significantly lower DFS(P = 0.039).Patients with HER4-positive and HER2-negative expression profiles had significantly longer DFS(P = 0.000) than other groups.Conclusion:HER4 expression is an independent predictor of breast cancer.Patients with HER4-positive have longer DFS,and HER4 can be a co-activator of ER and PR.更多还原